BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 19144521)

  • 1. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
    Matozaki T; Murata Y; Okazawa H; Ohnishi H
    Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CD47-SIRPα signalling system: its physiological roles and therapeutic application.
    Murata Y; Kotani T; Ohnishi H; Matozaki T
    J Biochem; 2014 Jun; 155(6):335-44. PubMed ID: 24627525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
    Veillette A; Chen J
    Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system.
    Okazawa H; Motegi S; Ohyama N; Ohnishi H; Tomizawa T; Kaneko Y; Oldenborg PA; Ishikawa O; Matozaki T
    J Immunol; 2005 Feb; 174(4):2004-11. PubMed ID: 15699129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
    Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
    Front Immunol; 2020; 11():18. PubMed ID: 32082311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential roles of SIRPα in homeostatic regulation of skin dendritic cells.
    Iwamura H; Saito Y; Sato-Hashimoto M; Ohnishi H; Murata Y; Okazawa H; Kanazawa Y; Kaneko T; Kusakari S; Kotani T; Nojima Y; Matozaki T
    Immunol Lett; 2011 Mar; 135(1-2):100-7. PubMed ID: 20955735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune animal models in the analysis of the CD47-SIRPα signaling pathway.
    Murata Y; Saito Y; Kaneko T; Kotani T; Kaneko Y; Ohnishi H; Matozaki T
    Methods; 2014 Jan; 65(2):254-9. PubMed ID: 24091004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
    Barclay AN; Van den Berg TK
    Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel CD47: SIRPα dependent mechanism for the activation of STAT3 in antigen-presenting cell.
    Toledano N; Gur-Wahnon D; Ben-Yehuda A; Rachmilewitz J
    PLoS One; 2013; 8(9):e75595. PubMed ID: 24073274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis.
    Oldenborg PA; Gresham HD; Lindberg FP
    J Exp Med; 2001 Apr; 193(7):855-62. PubMed ID: 11283158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD47: role in the immune system and application to cancer therapy.
    Hayat SMG; Bianconi V; Pirro M; Jaafari MR; Hatamipour M; Sahebkar A
    Cell Oncol (Dordr); 2020 Feb; 43(1):19-30. PubMed ID: 31485984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered proteins with sensing and activating modules for automated reprogramming of cellular functions.
    Sun J; Lei L; Tsai CM; Wang Y; Shi Y; Ouyang M; Lu S; Seong J; Kim TJ; Wang P; Huang M; Xu X; Nizet V; Chien S; Wang Y
    Nat Commun; 2017 Sep; 8(1):477. PubMed ID: 28883531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK/STAT- and phosphatidylinositol 3-kinase/Rac1/NAPDH oxidase/H2O2-dependent pathways.
    Alblas J; Honing H; de Lavalette CR; Brown MH; Dijkstra CD; van den Berg TK
    Mol Cell Biol; 2005 Aug; 25(16):7181-92. PubMed ID: 16055727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
    Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
    Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.